Previous Article | Next Article 
J Virol, July 1998, p. 5383-5391, Vol. 72, No. 7
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Characterization of the Proline-Rich Region of
Murine Leukemia Virus Envelope Protein
Bonnie
Weimin
Wu,1,2
Paula M.
Cannon,1,2,*
Erlinda M.
Gordon,1,3,4
Frederick
L.
Hall,5 and
W.
French
Anderson1,2,3
Gene Therapy Laboratories, Norris Cancer
Center,1
Department of Biochemistry and
Molecular Biology,2
Department of
Pediatrics,3
Division of
Hematology-Oncology,4 and
Department of
Cardiothoracic Surgery,5 University of
Southern California School of Medicine, Los Angeles, California 90033
Received 5 December 1997/Accepted 20 March 1998
 |
ABSTRACT |
Mammalian type C retroviral envelope proteins contain a variable
proline-rich region (PRR), located between the N-terminal receptor-binding domain and the more highly conserved C-terminal portion of the surface (SU) subunit. We have investigated the role of
the PRR in the function of murine leukemia virus (MuLV) envelope
protein. In the MuLVs, the PRR contains a highly conserved N-terminal
sequence and a hypervariable C-terminal sequence. Despite this
variability, the amphotropic PRR could functionally substitute for the
ecotropic PRR. The hypervariable region of the PRR was not absolutely
required for envelope protein function. However, truncations in this
region resulted in decreased levels of both the SU and TM proteins in
viral particles and increased amounts of the uncleaved precursor
protein, Pr85. In contrast, the N-terminal conserved region was
essential for viral infectivity. Deletion of this region prevented the
stable incorporation of envelope proteins into viral particles in spite
of normal envelope protein processing, wild-type levels of cell surface
expression, and a wild-type ability to induce syncytia in an XC cell
cocultivation assay. However, higher levels of the SU protein were shed
into the supernatant, suggesting a defect in SU-TM interactions. Our data are most consistent with a role for the PRR in stabilizing the
overall structure of the protein, thereby affecting the proper processing of Pr85, SU-TM interactions, and the stable incorporation of
envelope proteins into viral particles. In addition, we have demonstrated that the PRR can tolerate the insertion of a
peptide-binding domain, making this a potentially useful site for
constructing targetable retroviral vectors.
 |
INTRODUCTION |
Retroviruses enter their host cells
through an interaction between the viral envelope protein and a
specific cell surface receptor (1, 19, 42). Binding of the
envelope protein to its receptor leads to the fusion of viral and host
cell membranes, which allows internalization of the viral core.
Retroviral envelope proteins are composed of two subunits, a surface
(SU) protein which binds to the cellular receptor (42), and
a transmembrane (TM) protein which is required for the membrane fusion
events after receptor binding (43).
Within the type C mammalian retroviruses, the N-terminal portion of SU
is responsible for receptor recognition (3, 23, 25). The
more conserved C-terminal region of the protein is believed to
associate with the TM protein and to be involved in the postbinding
events that lead to fusion of the viral and cellular membranes
(14, 30, 32, 36). The SU proteins of the type C mammalian
retroviruses also contain a segment of proline-rich sequence between
the N-terminal receptor binding domain and the more conserved
C-terminal portion (21). This proline-rich region (PRR) is
found in the SU proteins of the gibbon ape leukemia viruses (7), the feline leukemia viruses (FeLVs) (9, 26),
and the different MuLV subtypes (5, 21, 28). The PRR
contains a conserved N-terminal domain of 14 or 15 amino acids, but the remainder of the PRR sequence varies both in length and in sequence among different viruses (21, 28).
The role of the PRR in envelope protein function has not been
determined. It has been speculated that the PRR might participate in
postbinding events during viral entry, since point mutations and linker
insertions in this region produce fusion-defective envelope proteins
(2, 14) and can prevent the stable association of the SU and
TM subunits (14). In addition, the PRR has been shown to be
capable of influencing the receptor recognition properties of the
N-terminal region of SU (3, 28), although whether this is a
result of the PRR containing a direct receptor contact point or whether
it is due to a more indirect effect on the structure of this region
remains to be determined. Structural studies of a peptide corresponding
to the FeLV PRR indicated that this region may exist as a polyproline
-turn helix with a propensity to oligomerize, that could fold into a
separate domain in SU (11).
We wished to study in more detail the role of the PRR in MuLV envelope
protein function. We looked initially at the interchangeability of the
PRRs from the ecotropic and amphotropic MuLV envelope proteins and
demonstrated that the amphotropic PRR could functionally substitute for
the ecotropic region, despite differences in the length and sequence of
the variable regions. In addition, analysis of a series of truncations
of the variable C-terminal region revealed that over half of the
sequence could be truncated without significant loss of envelope
protein function, although further truncations had effects on envelope
protein incorporation and the stability of SU-TM interaction. In
contrast, we found that the N-terminal conserved region was absolutely
essential for viral infectivity. Deletion of this sequence prevented
the incorporation of envelope proteins into virions and completely
abolished the viral titer.
One of the major goals of retroviral vector development is the
generation of targetable vectors that could be used to achieve cell-specific gene delivery (4, 6). The apparent flexibility of the PRR variable sequence led us to investigate whether this region
would be able to tolerate the insertion of a peptide that could
redirect binding of the envelope protein to a new cell surface protein.
As a proof of this principle, we inserted a 16-amino-acid collagen-binding peptide into different locations in the PRR. Retroviral vector particles containing such chimeric envelope proteins
achieved a wild-type titer on NIH 3T3 cells and conferred specific
binding to collagen, indicating that the PRR may be a promising site
for ligand insertion when constructing targetable vectors.
 |
MATERIALS AND METHODS |
Cell lines.
NIH 3T3 and 293T cells were maintained in
Dulbecco's modified Eagle's medium (GIBCO-BRL, Grand Island, N.Y.).
XC cells were grown in Eagle's minimal essential medium (GIBCO-BRL).
Both media were supplemented with 10% fetal calf serum (HyClone,
Logan, Utah) and 2 mM glutamine.
Envelope protein expression plasmids.
pCEE+ is an expression
plasmid for the wild-type Moloney MuLV (MoMuLV) ecotropic envelope
protein (23); pCAE contains the 4070A amphotropic envelope
protein (25). Two restriction sites, AvrII and
NgoMI, were generated as silent point mutations by
recombinant PCR (18) at the 5' and 3' ends of the ecotropic
PRR, respectively, creating plasmid pCEE*. The oligonucleotides used
were 5'-GACTCAGATACCAAAACCTAGGACCCCGCGTC-3' and
5'-CCCAACTTCCACCGGCCGGCACGGAAAATAGGCTGC-3'; the
AvrII and NgoMI restrictions sites are
underlined. The amphotropic PRR was amplified by PCR from plasmid pCAE
with the addition of AvrII and NgoMI sites at the
ends of the PCR fragment and used to replace the PRR in pCEE*,
generating plasmid E/A-PRR. Similarly, C-terminal and N-terminal PRR
truncation mutants of E/A-PRR were created by replacing the CEE* PRR
with fragments of the amphotropic PRR of different lengths, generated
as PCR products with terminal AvrII and NgoMI
sites. All mutants were confirmed by sequencing the final constructs.
To facilitate the insertion of a 16-amino-acid peptide containing a
collagen-binding domain from von Willebrand's factor (39) into the PRR of E/A-PRR, the restrictions sites PstI and
StuI were generated in the PRR as nonsilent mutations
through recombinant PCR at the sites shown in Fig. 7. The
oligonucleotides used were 5'-GCCACCTAGCCCCCTGCAGACCAGTTACCCCCCT-3' for
PstI and
5'-ACCAGTACACCCTCAGGCCTCCCTACAAGTCCAAGT-3' for
StuI. The collagen binding peptide sequence was created as two overlapping oligonucleotides, flanked by either PstI
ends (insert 1) or PstI and StuI ends (insert 2).
Insert 1 was encoded by the sequence
5'-GGGCCATATGTGGCGCGAACCGAGCTTCATGGCTCTGAGCGGTGCTAGCCTGCA-3', and
insert 2 was encoded by the sequence
5'-GGGCCATATGTGGCGCGAACCGAGCTTCATGGCTCTGAGCGGTGCTTCAGG-3'.
Retroviral vector production and titer determination.
Retroviral vectors were produced by transient transfection of 293T
cells by calcium phosphate precipitation, essentially as described
previously (16, 37). The plasmids used were the MoMuLV
gag-pol expression plasmid pHIT60 (37); the
retroviral vector pCnBg (16), which expresses
lacZ and neo; and an env expression
plasmid. At 16 h posttransfection, the cells were washed and fresh
medium was added. At 48 h later, the culture supernatant was
collected and filtered through a 0.45-µm-pore-size filter and either
used immediately or stored at
70°C. The virus titer was determined
as G418-resistant CFU per milliliter. For titer determination NIH 3T3
cells (3 × 104 cells per 30-mm well) were plated in 3 ml of medium; 18 h later, the medium was replaced with 1 ml of
appropriately diluted viral supernatant containing Polybrene (8 µg/ml) and the mixture was incubated for 2 h at 37°C. An
additional 2 ml of medium was then added, and the cultures were
incubated for a further 18 h. The cells were then selected for 10 days in medium containing 0.6 mg of G418 per ml, and resistant colonies
were scored by methylene blue staining.
Western blot analysis of envelope proteins in viral particles and
cell lysates.
Retroviral particles generated by transient
transfection of 293T cells were pelleted through 20% sucrose at
16,000 × g and 4°C for 30 min. Viral pellets were
resuspended in 30 µl of 2× sodium dodecyl sulfate (SDS) gel-loading
buffer (100 mM Tris-HCl [pH 6.8], 4% SDS, 20% glycerol, 0.01%
bromphenol blue, 1.4 M
-mercaptoethanol) and boiled for 5 min. Viral
protein samples were resolved on a precast 8 to 16% polyacrylamide gel
(Novex, San Diego, Calif.) and transferred onto an Immobilon membrane
(Millipore, Bedford, Mass.). The blot was blocked overnight at 4°C in
5% powdered milk in TBS (50 mM Tris-HCl [pH 7.5], 150 mM NaCl,
0.25% Tween 20), and incubated with primary antibodies at room
temperature for 2 h. After being washed in TBS buffer for 30 min,
the blots were incubated with secondary antibodies for 1 h at room
temperature and then given a further 30-min wash in TBS. Specific
proteins were visualized with the enhanced chemiluminescence detection system (Amersham International plc., Arlington Heights, Ill.). The
primary antibodies used were goat anti-Rauscher MuLV gp69/71, 1:3,000
dilution (Quality Biotech, Camden, N.J.; lot 79S656); goat anti-Raucher
MuLV p30, 1:10,000 dilution (Quality Biotech; lot 78S221); and rat
anti-AKR MuLV p15E (BABCO, Berkeley, Calif.; lot 42/114)
(31). The secondary antibodies were horseradish peroxidase-conjugated rabbit anti-goat immunoglobulin G (IgG) (1:10,000) and horseradish peroxidase-conjugated goat anti-rabbit IgG
(1:10,000) (Pierce, Rockford, Ill.).
To analyze the form of the envelope proteins present in cell lysates,
293T cells were transfected with envelope protein expression plasmids
(30 µg per 10-cm plate) and lysates were prepared by incubating the
cells in 500 µl of lysis buffer (20 mM Tris-HCl [pH 7.5], 1%
Triton X-100, 0.05% SDS, 5 mg of sodium deoxycholate per ml, 150 mM
NaCl, 1 mM phenylmethylsulfonyl fluoride) for 10 min at 4°C and
centrifuging them at 10,000 × g for 10 min to pellet the nuclei. Envelope proteins were denatured by treating the lysates with 0.5% SDS and 1%
-mercaptoethanol at 100°C for 5 min and then deglycosylated with 50 mM sodium phosphate (pH 7.5)-1% Nonidet P-40 (NP-40)-500 U of N-glycosidase F (New England Biolabs,
Beverly, Mass.) at 37°C for 1 h. Envelope proteins were detected
by Western blotting as described above.
Cocultivation fusion assay.
293T cells (6 × 105 cells) were plated in a 60-mm dish and transfected with
15 µg of envelope expression vector DNA by calcium phosphate
precipitation. At 16 h posttransfection, the cells were washed and
fresh medium was added. Nonirradiated XC cells (106 cells)
were added to the plate 24 h posttransfection, and the culture was
incubated for an additional 24 h at 37°C. Syncytia were observed
and counted by light microscopy after staining of the cells with 1%
methylene blue in methanol.
Cell surface expression of envelope proteins.
293T cells in
a 60-mm plate were transiently transfected with 15 µg of an envelope
expression vector. At 48 h posttransfection, the cells were
harvested with enzyme-free cell dissociation solution (GIBCO-BRL) and
washed with phosphate-buffered saline (PBS). The cells
(106) were incubated at 4°C for 1 h with the rat
monoclonal antibody 83A25 (10), which recognizes the C
terminus of MoMuLV gp70 envelope protein. The cells were washed with
10% goat serum in PBS and incubated with fluorescein
isothiocyanate-labeled goat anti-rat IgG (Kirkegaard & Perry
Laboratories, Inc., Gaithersburg, Md.) at 4°C for 1 h. They were
then washed again and fixed in 4% paraformaldehyde in PBS. The
fluorescence intensity of the cell samples were measured with a FACStar
Plus flow cytometer (Becton Dickinson, San Jose, Calif.).
Immunoprecipitation of SU from cell culture supernatants.
293T cells in a 60-mm plate were transiently transfected with 15 µg
of an envelope expression vector, and SU was immunoprecipitated from
culture supernatants as described previously (45). At
48 h posttransfection, the cells were washed with PBS and
incubated in cell-labeling medium (Dulbecco's modified Eagle's medium
without methionine and cysteine and containing 10% dialyzed fetal calf serum) for 1 h at 37°C. The cells were then incubated for 8 h in cell-labeling medium containing 100 µCi each of
[35S]methionine and [35S]cysteine
(Amersham), harvested, and lysed in immunoprecipitation buffer (10 mM
Na2HPO4 [pH 7.4], 150 mM NaCl, 0.5% Triton
X-100, 0.1% SDS, 0.05% sodium deoxycholate) for 20 min at 4°C.
After centrifugation at 4°C for 10 min at 16,000 × g, the supernatants were incubated with 8 µl of goat
anti-Rauscher MuLV gp69/71 antiserum (Quality Biotech; lot 79S656) and
20 µl of protein G-Sepharose (Sigma, St. Louis, Mo.) overnight at
4°C. The samples were then centrifuged at 80 × g for
2 min, and the pellets were resuspended and washed once each in washing
buffer 1 (100 mM Tris-Cl [pH 7.5], 150 mM NaCl, 2 mM EDTA, 0.2%
NP-40), washing buffer 2 (100 mM Tris-Cl [pH 7.5], 500 mM NaCl, 2 mM
EDTA, 0.2% NP-40), and washing buffer 3 (10 mM Tris-Cl [pH 7.5]).
The samples were centrifuged at 80 × g for 1 min and
resuspended in 30 µl of 2× SDS gel-loading buffer and boiled for 5 min. They were resolved by SDS-polyacrylamide gel electrophoresis on 8 to 16% polyacrylamide gels. The gels were fixed in 5% acetic
acid-5% isopropanol for 20 min, washed in water for 15 min, and
soaked in Autofluor (National Diagnostics, Atlanta, Ga.) for 30 min to
enhance the signal. The gel was dried and exposed to BioMax MR film
(Eastman Kodak, Rochester, N.Y.) at
70°C overnight.
Collagen-binding assay.
Each well of a 24-well
collagen-coated plate (Becton-Dickinson Labware, Bedford, Mass.) was
incubated with 500 µl of retroviral vector supernatant for 1 h
at room temperature, washed with PBS, and incubated for 1 h with
500 µl of hybridoma supernatant containing the rat monoclonal anti-SU
antibody, 83A25 (10). Following a further PBS wash, the well
was incubated with 200 µl of goat anti-rat antibody (Zymed, San
Francisco, Calif.) at a 1:50 dilution for 30 min, washed with PBS,
incubated with 200 µl of rat peroxidase anti-peroxidase antibody
(Sternberger Monoclonals Inc., Lutherville, Mass.) at a 1:50 dilution
for 30 min, and washed with PBS. Finally, 500 µl of
diaminobenzidine/nickel chloride was added and the resulting color
change was monitored at 600 nm with a Rainbow Spectra plate reader.
 |
RESULTS |
Generation of a chimeric ecotropic envelope protein containing the
amphotropic PRR.
The MuLV envelope protein is composed of two
subunits, the SU protein, gp70, and the TM protein, p15E, which are
cleaved from a precursor protein, Pr85 (19). Amino acid
sequence alignments of the SU proteins of the type C retroviruses have
previously identified a variable PRR located between the N-terminal
receptor-binding domains and the more highly conserved C-terminal
regions (21). In the MuLVs, the PRR is composed of 30 to 60 amino acids, with a proline content of about 30%. The N-terminal 14 or
15 amino acids form a distinct motif, which is highly conserved in all the major subtypes of the MuLVs, while the remainder of the PRR varies
in both length and sequence (Fig. 1A).

View larger version (30K):
[in this window]
[in a new window]
|
FIG. 1.
(A) Sequence alignment of the PRR from several mammalian
type C retroviruses. The PRR links the N-terminal receptor-binding
domain and the more highly conserved C-terminal part of the SU protein.
The N-terminal region of the PRR is conserved among the different
viruses and is highly conserved within the different MuLV subtypes
shown. In contrast, the C-terminal portion of the PRR varies in both
sequence and length. (B) Construction of envelope protein mutants.
AvrII and NgoMI restriction enzyme sites were
introduced into the MoMuLV SU to flank the PRR. These sites were used
to replace the ecotropic PRR with either the full-length amphotropic
PRR sequence (E/A-PRR) or C-terminal truncations of that sequence. The
truncations are named according to the number of amino acids deleted
from the C terminus, and construct N-14 has the N-terminal 14 conserved
amino acids deleted. The asterisks indicate a potential N-linked
glycosylation site present in the amphotropic PRR.
|
|
To investigate the requirements for the function of the PRR, we
constructed a chimeric envelope protein, E/A-PRR, in which the
amphotropic PRR was used to exactly replace the ecotropic MoMuLV PRR
(Fig. 1B). The amphotropic sequence is 14 amino acids longer than the
ecotropic PRR, contains an additional potential N-linked glycosylation
site, and varies considerably in sequence from the ecotropic PRR in the
C terminus. We produced retroviral vector particles containing the
E/A-PRR protein and tested the function of the protein by analyzing the
ability of these retroviral vectors to transduce NIH 3T3 cells. Vectors
containing the E/A-PRR protein were able to transduce NIH 3T3 cells at
titers similar to those for the wild-type ecotropic envelope protein
(Table 1), indicating that the
amphotropic sequence could functionally substitute for the ecotropic
PRR and that the precise PRR sequence was not essential for the
function of the MoMuLV envelope protein.
Minimal length of PRR required for envelope protein function.
Although the precise sequence of the ecotropic PRR was not required for
the function of the MoMuLV envelope protein, the suggested role of the
PRR as a linker between two different domains of SU may depend on both
the high proline content of the region and the length, and therefore
the flexibility, of this sequence. To investigate these requirements,
we constructed a series of C-terminal truncations of the PRR sequence
in E/A-PRR (Fig. 1B) and analyzed the ability of retroviral vectors
carrying these proteins to transduce NIH 3T3 cells. This analysis
revealed that extensive deletions of the C-terminal hypervariable
region of the PRR could be made with little effect on viral infectivity
(Table 1). The deletions of 29 and 34 of the 58 amino acids of the
amphotropic PRR (constructs C-29 and C-34) resulted in viral titers
that were 62 and 21% of those for the wild-type ecotropic envelope
protein, respectively. Even the deletion of 49 residues in C-49
produced viral particles that gave titers that were 6% of the
wild-type level, even though the deletion in C-49 removed all of the
C-terminal variable region and 4 residues of the conserved N-terminal
region. However, when the truncation was extended a further 5 amino
acids into the N-terminal region (construct C-54), the envelope protein
totally lost function and the viral titer became zero.
These data implicated the N-terminal motif in envelope protein
function. To investigate more precisely the role of the conserved N
terminus in envelope protein function, we deleted this region from
E/A-PRR to produce mutant N-14 (Fig. 1B). Mutant N-14 was assessed for
its ability to transduce NIH 3T3 cells and, similar to mutant C-54, was
found to give no titer (Table 1).
PRR mutants differentially affect virus-cell and cell-cell
fusion.
We examined the effects of the PRR deletions on the levels
of cell surface expression of the envelope proteins and on the ability
of the envelope proteins to direct cell-cell fusion. All of the mutant
proteins were detected on the surface of transfected 293T cells,
although mutants C-34 and C-39 were present at about 50% the level of
the wild-type protein and mutant C-54 was present at only about 20% of
the wild-type level (Table 1).
The ability of the proteins to direct cell-cell fusion was measured in
a cocultivation assay between 293T cells expressing the envelope
proteins and the indicator XC cell line which expresses the ecotropic
receptor. XC cells fuse with cells expressing the ecotropic envelope
protein on their surface, resulting in the formation of syncytia. This
assay revealed that cell-cell fusion was more sensitive to C-terminal
truncations of the PRR than was virus-cell fusion as measured by NIH
3T3 cell transduction. Defects in syncytium formation were first
observed with the removal of only 24 residues, and truncations beyond
29 residues resulted in completely nonfusogenic proteins.
A different phenotype was observed for the N-terminal deletion mutant
N-14. This protein was present at normal levels on the cell surface and
resulted in wild-type levels of syncytia (Fig. 2). However, despite the fusogenicity of
this protein in cell-cell assays, retroviral vector particles produced
with this construct gave no titer on NIH 3T3 cells (Table 1).

View larger version (79K):
[in this window]
[in a new window]
|
FIG. 2.
Fusogenicity of the N-14 mutant. 293T cells expressing
the wild-type CEE+ or N-14 mutant envelope proteins were cocultivated
at 37°C with XC indicator cells, which express the ecotropic
receptor. Both envelope proteins resulted in equivalent levels of
syncytium formation.
|
|
Effects of deletions of the PRR on envelope protein incorporation
into viral particles.
Western blot analysis was carried out to
examine the levels of the C-terminally truncated envelope proteins
within viral particles (Fig. 3). The SU
subunit of the full-length protein, E/A-PRR, ran with a different
mobility from the parental MoMuLV envelope protein, CEE+, presumably
due to the presence of 14 additional amino acids, an extra N-linked
glycosylation site in the amphotropic PRR, and several potential
additional O-linked glycosylation sites (Fig. 1). Deletions C-14 and
C-19 resulted in envelope proteins that were incorporated into the
viral particles at levels comparable to that of the wild-type protein,
but the level of envelope protein associated with viral particles
gradually decreased for truncations C-24 to C-49, as evidenced by the
lower levels of both the SU and TM subunits. For this group of
proteins, an additional band was detected by the anti-SU antiserum,
which migrated at a higher position than SU. The intensity of the band
increased as more amino acids were deleted, and for constructs C-44 and
C-49, the majority of the protein recognized by the anti-SU antiserum
was the higher-mobility form.

View larger version (31K):
[in this window]
[in a new window]
|
FIG. 3.
Western blot analysis of virion-associated envelope
proteins. (A and B) Viral particles were pelleted through 20% sucrose,
and specific proteins were detected including the SU protein and the
viral capsid protein, CA (A) and TM protein (B). The MuLV TM protein
exists in two forms, full-length p15E and a truncated form p12E
(15, 20), both of which can be seen. Mock transfection
results in no envelope protein. (C) Viral proteins were probed with
anti-TM antibody, revealing the presence of Pr85 in virions for
constructs C-44 and C-49.
|
|
We investigated the nature of the higher-migrating band observed for
proteins C-24 to C-49. Probing a Western blot of mutants C-44 and C-49
with an anti-TM antibody revealed that this protein was probably the
uncleaved precursor envelope protein, Pr85 (Fig. 3C). It is possible
that the presence of this precursor protein in particles reflected an
underlying defect in the processing of Pr85 to the SU and TM subunits.
Accordingly, we analyzed the form of the envelope proteins present in
the lysates of transfected cells. To clearly distinguish between Pr85,
SU, and various processing intermediates of Pr85, we treated the
lysates with an N-glycosidase and also included marker
protein constructs that expressed only the MoMuLV SU or Pr85 proteins
(Fig. 4A). These results demonstrated that while approximately equal amounts of the Pr85 and SU proteins could be observed for the wild-type protein CEE+, the parental hybrid
E/A-PRR, and the mutants N-14 and C-14, only a single band was observed
for mutants C-44, C-49, and C-54. Reduced levels of Pr85 processing to
SU were observed for the truncations C-19 to C-39 (Table 1 and data not
shown). Probing the cell lysates with an anti-TM antibody revealed that
the single species observed for mutants C-44, C-49, and C-54 was Pr85
(Fig. 4B).

View larger version (60K):
[in this window]
[in a new window]
|
FIG. 4.
Envelope proteins in cell lysates. (A) Cell lysates of
293T cells expressing envelope proteins were deglycosylated and probed
with an anti-SU antibody. Construct SU is terminated at the natural
SU-TM cleavage site and therefore produces only SU, while construct
Pr85 contains a mutated cleavage site and produces only Pr85. Mock
transfection results in no envelope protein. (B) Deglycosylated cell
lysates were probed with anti-TM antibody, which detects Pr85 and the
processed TM protein.
|
|
Mutant C-54, which contains a deletion extending into the N-terminal
conserved region, did not result in any detectable SU, TM, or Pr85
proteins in viral particles (Fig. 3). Although Pr85 was seen in cell
lysates (Fig. 4), C-54 differed from mutants C-44 and C-49 in that no
Pr85 was subsequently incorporated into viral particles. In addition,
this mutant was present at a much lower level on the surface of cells
(Table 1). These defects alone could account for the lack of titer and
the loss of the ability to promote cell-cell fusion observed with this
mutant (Table 1).
N-14 is a temperature-sensitive incorporation mutant.
A
possible explanation for the lack of infectivity of the N-14 mutant,
despite its ability to promote cell-cell fusion, is that this protein
is not stably incorporated into viral particles. Accordingly, we used
Western blot analysis to investigate the envelope protein content of
the viral particles. The results revealed that there was no detectable
envelope protein present in the viral particles (Fig.
5A), even though the N-14 mutant
displayed normal processing of the precursor Pr85 to the mature SU
protein in cell lysates (Fig. 4).

View larger version (40K):
[in this window]
[in a new window]
|
FIG. 5.
N-14 is a temperature-sensitive incorporation mutant.
(A) N-14 is undetectable in viral particles produced at 37°C. (B)
N-14 is incorporated into viral particles at a low level at 32°C.
|
|
We investigated the possibility that the defect in the N-14 envelope
protein was a temperature-sensitive mutation by analyzing the envelope
protein content of virions harvested at 32°C. Western blot analysis
revealed that the N-14 mutant was present in viral particles at low
levels at this temperature (Fig. 5B). In addition, N-14 virions
harvested at 32°C gave a titer of 1.4 × 104 CFU/ml
on NIH 3T3 cells, which was 10% of the value obtained for the
wild-type envelope protein at this temperature. These results therefore
demonstrated that N-14 is a temperature-sensitive incorporation mutant.
PRR affects SU-TM interactions.
Previous linker insertion
mutations in the PRR have been shown to result in a more labile SU-TM
interaction, resulting in greater shedding of the SU subunit from viral
particles (14). We therefore investigated the effects of the
PRR mutants on SU-TM interactions by analyzing the amount of free SU
protein that could be immunoprecipitated from the supernatants of cells
expressing the envelope protein mutants (Fig.
6).

View larger version (82K):
[in this window]
[in a new window]
|
FIG. 6.
Immunoprecipitation of SU protein from cell culture
supernatants. SU proteins were immunoprecipitated from the supernatants
of 293T cells transiently transfected with various envelope protein
expression plasmids.
|
|
This analysis revealed that the progressive shortening of the
C-terminal region of the PRR up to mutant C-29 resulted in an increased
tendency to shed SU into the culture supernatant. Mutants C-34 and C-39
did not appear to continue this trend, since they produced smaller
amounts of free SU in the supernatant than did mutant C-29, but both of
these proteins were present at notably lower levels on the cell
surface. Mutants C-44 and C-49 produced very little free SU in the
supernatants of transfected cells. However, both of these proteins
demonstrated very poor processing of Pr85 to SU, as evidenced by the
lack of SU detected in cell lysates (Fig. 4) and the high levels of
incorporation of Pr85 into viral particles (Fig. 3).
Higher levels of SU were seen in the supernatants of cells transfected
with mutant N-14 and in particular with mutant C-54. While neither
protein is present in viral particles, the two proteins have distinct
properties (Table 1; Fig. 4). For C-54, no processed SU could be
detected in cell lysates and very little envelope protein was present
on the cell surface. In contrast, mutant N-14 produced normal levels of
both Pr85 and SU in cell lysates and was readily detectable on the cell
surface.
Insertion of a collagen-binding peptide into the PRR.
Since
the PRR could tolerate changes in both the actual sequence of its
C-terminal region and its overall length, we tested whether this region
would allow the insertion of a peptide-binding domain, in order to
generate a targetable retroviral vector. As a proof of the principle, a
16-amino-acid peptide containing the collagen-binding domain from von
Willebrand's factor (39) was inserted into two different
sites in the PRR of protein E/A-PRR (Fig.
7A). The chimeric envelope proteins so
generated were efficiently incorporated into retroviral vectors (Fig.
7B) and gave titers on NIH 3T3 cells that were similar to those
obtained with the wild-type protein (Table
2), demonstrating that insertions in the
PRR did not disrupt envelope protein function.

View larger version (33K):
[in this window]
[in a new window]
|
FIG. 7.
Insertion of a collagen-binding domain into the PRR of
E/A-PRR. (A) A 16-amino-acid peptide containing a collagen-binding
domain (underlined) from von Willebrand's factor (39) was
inserted into two sites in the PRR of E/A-PRR. PstI and
StuI sites were created to facilitate these insertions.
Insert 1 was at the PstI site, and insert 2 was a
replacement of the PstI-StuI fragment. The amino
acids marked with asterisks are nonsilent mutations created by the
generation of the PstI and StuI sites. (B)
Western blot analysis shows that both of the chimeric envelope proteins
were incorporated efficiently into viral particles.
|
|
To assess whether the inserted peptide could confer binding to
collagen, we analyzed the ability of retroviral particles pseudotyped with the chimeric envelope proteins to bind to collagen-coated plates.
Both of the chimeric envelope proteins bound virions to the plates,
while the wild-type MoMuLV envelope protein did not (Table 2).
 |
DISCUSSION |
Three distinct domains are present in the SU proteins of the type
C mammalian retroviruses. The N-terminal region, which displays the
most variability between different viruses, interacts with the specific
viral receptor and thereby determines the tropism of the virus
(42), while the more highly conserved C-terminal region
associates with the TM subunit (30, 32). These two regions
are separated by a PRR of variable length and sequence. The location
and high proline content of the PRR have led to speculation that this
region could serve as a flexible linker or hinge region, important for
transmitting the conformational changes that are thought to occur in
the retroviral envelope protein complex after binding to a receptor
(13, 35). As such, it may function in a similar way to the
hinge regions of immunoglobulins, which introduce flexibility into the
antigen-binding arms to allow optimal interactions with antigens
(40).
Our analysis of the role of the PRR in the MuLVs initially investigated
the ability of the amphotropic PRR to functionally substitute for the
shorter ecotropic PRR in the MoMuLV envelope protein. We constructed a
chimeric protein, E/A-PRR, which proved to be fully functional and to
produce retroviral vectors with titers that were 46% of those for the
wild-type ecotropic parent. This result indicated that it is not the
actual sequence of the PRR that is important for function but, rather,
some overall feature of the region, such as the high proline content.
We also demonstrated that a 16-amino-acid peptide could be inserted
into E/A-PRR, making the PRR 31 amino acids longer than the original
ecotropic region without affecting envelope protein function. The
ability of the PRR to tolerate this insertion suggests that this region
could be used for inserting novel peptide-binding domains to generate targetable retroviral vectors.
We observed that E/A-PRR migrated at a higher position on an
SDS-polyacrylamide gel than did the wild-type MoMuLV envelope protein.
This result is most probably due to the presence of the additional
N-linked glycosylation site that is predicted to be in the amphotropic
PRR. This assumption is consistent with the observation that the
truncated amphotropic PRR present in protein C-24, which no longer
contains the consensus N-linked glycosylation site, produced a protein
that ran at the same size as the wild-type protein. Alternatively, it
has been reported that point mutations in the ecotropic PRR can affect
the mobility of both Pr85 and SU and that this was the result of
differential glycosylation (2).
The PRR contains two distinct sequence motifs. The N-terminal 14 or 15 amino acids are conserved in all of the type C mammalian retroviruses,
while the C-terminal region of between 31 and 61 residues varies
considerably in its primary sequence. The PRR has been proposed to form
a polyproline
-turn helix (11), with 10 strong turns
predicted in both the amphotropic sequence (41) and the FeLV
sequence (11). Of these, three are present in the N-terminal
region. It is likely that the PRR forms an exposed loop between the N-
and C-terminal domains of SU (11). The presence of N-linked
glycosylation sites in several PRR sequences and the high tendency of
this region to induce neutralizing antibodies in FeLV (26,
27) are consistent with the PRR being surface exposed.
Furthermore, we have demonstrated that the insertion of a
collagen-binding domain from von Willebrand's factor into this region
allowed the resulting envelope protein to bind to collagen, which is
also indicative of an accessible region.
The C-terminal deletion mutants we produced in E/A-PRR had several
effects on envelope protein function. Initially, the deletion of just
14 amino acids, which shortened the amphotropic PRR to the same length
as the original ecotropic PRR, restored the titer to near-wild-type
levels. Subsequent truncations of up to 29 amino acids had very little
effect on the titer. However, the sequential truncation of the
C-terminal region did result in decreased levels of the processed SU
and TM subunits of the envelope protein being incorporated into
virions. In addition, we observed an increasing amount of the uncleaved
precursor protein, Pr85, in virions. The decreases in both cell-cell
fusion and transduction efficiency that we observed for mutants C-24 to
C-49 could be secondary to these incorporation defects. We could always
detect some form of envelope protein present on the cell surface for
all of the mutants, although C-54 was detected at much lower levels.
However, it is possible that the major species detected for mutants
C-39 to C-49 was the uncleaved precursor Pr85.
Cleavage of the precursor envelope protein into the mature SU and TM
subunits is essential for retroviral infectivity. While mutation of the
cleavage site can force the incorporation of a low level of uncleaved
precursor protein into virions, the resulting particles are
noninfectious (references 8, 12, and
24 and data not shown). Truncation of the PRR
C-terminal region in mutants C-24 to C-49 resulted in a
decreased efficiency of Pr85- to-SU processing in cell lysates and
the appearance of increasing amounts of Pr85 in viral particles.
Despite the high levels of Pr85 and low levels of SU and TM proteins in
virions, retroviral vectors containing the C-terminal truncation
mutants up to C-49 remained infectious. It seems likely that the low
level of properly cleaved protein detected for mutants C-39 to C-49 was
sufficient to allow viral entry. These results indicate that virus-cell
fusion can occur efficiently even when only a small amount of processed
envelope protein is present. This observation contrasts with the
results from the cell-cell fusion assay, in which we detected hardly
any syncytia for mutant C-29 and none for mutant C-34, despite their abilities to produce almost wild-type titers in retroviral vectors. These results indicate that cell-cell fusion has different requirements from virus-cell fusion, as we (46) and others (14, 29,
44) have previously noted.
Removal of the N-terminal domain of the PRR in mutant N-14 resulted in
an envelope protein that was not incorporated into virions at all at
37°C, although low levels could be detected at 32°C. This result
occurred despite the presence of normal levels of Pr85 processing in
cell lysates and wild-type levels of cell surface protein. Furthermore,
the cell surface N-14 protein was fully able to induce cell-cell fusion
in a cocultivation assay. Higher levels of SU were shed into the
supernatant of transfected cells than occurred with the wild-type
protein, suggesting that one defect in this protein may be a decreased
stability in the interaction between the SU and TM subunits. Previous
linker insertions in the N-terminal region of the MoMuLV PRR have also
been reported to produce viruses with a temperature-sensitive phenotype
(14). These mutant virions incorporated only SU and were
infectious at 32°C. Similar to the N-14 mutant, they also had a
higher tendency to shed SU into the supernatant than did the wild-type
virus. However, these mutants induced syncytia only at 32°C, in
contrast to N-14, which was also fusogenic at 37°C.
Decreased affinity between the SU and TM subunits can result in the
loss of SU, leaving the remaining TM protein unstable and rapidly
degraded, as has previously been suggested for mutants of MoMuLV
(14) and human immunodeficiency virus type 1 (17). However, this explanation is at odds with the
apparently normal cell surface levels of the N-14 mutant and its
ability to induce cell-cell fusion. It is conceivable that the N-14
deletion somehow prevented the incorporation of the envelope
protein into budding viral cores, although defects in envelope
protein incorporation have been observed only with certain mutations in
the cytoplasmic tail of the MoMuLV protein (20). An
alternative explanation could be that the association of the N-14
protein with virions decreased the stability of this protein. Envelope
protein incorporated into MuLV cores has the C-terminal 16 amino acids
of the cytoplasmic tail (the R peptide) removed by the viral protease.
This processing enhances the fusogenicity of the wild-type
envelope protein (33, 34) and could possibly strain an
already weakened SU-TM interaction in mutant N-14, leading to the
loss of SU and the rapid degradation of TM.
A defect in SU-TM association could also account for the
phenotype observed with protein C-54. This truncation
retained only 6 amino acids of the N-terminal conserved domain of
the PRR with none of the C-terminal region and only 1 of the 10 predicted
-turns in this region (11). Mutant C-54
resulted in the largest amounts of SU shed into the culture
supernatant and had only a very low level of envelope protein that
could be detected on the cell surface. In addition, only Pr85 and no
processed SU could be detected in cell lysates. Since the protein was
detected at only very low levels on the cell surface and in virions, it
was not surprising that C-54 was unable to cause either cell-cell
fusion or virus-cell fusion.
The underlying cause of the defect in mutant C-54 is unclear. It is
possible that this large truncation in the PRR destabilized SU-TM
interactions so that processed envelope protein was not stably
expressed on the cell surface. This could result in both a low level of
detection of cell surface envelope protein, a lack of SU protein
detected in the cell lysates, and a large amount of free SU shed into
the culture supernatant. It is also possible that different pathways in
the cell can be used to transport the envelope protein and that the
envelope protein shed into the supernatant is transported differently
from the protein that ultimately ends up on the cell surface. Notably,
two distinct populations have previously been detected for
membrane-associated and secreted simian immunodeficiency virus SU
(38).
Previous mutational analyses of this region have demonstrated a role
for the PRR in SU-TM association, the stable incorporation of envelope
protein into virions, envelope protein-mediated cell-cell fusion, and
viral infectivity (2, 14). Our analysis of the E/A-PRR
deletion mutants indicates that the primary defects in these mutants
are the ability of processed envelope protein to be incorporated into
virions and stable SU-TM associations. Similar effects on both Pr85
cleavage and SU-TM association have been reported for mutations in the
C-terminal region of the Friend MuLV SU (22). These effects
are consistent with the PRR being important for the overall folding of
the envelope protein, which in turn could influence the rate of
transport of the protein through the export pathway, the efficiency of
SU-TM cleavage, and the consequent stability of the noncovalently
linked SU and TM proteins in the final envelope protein complex. The
partially temperature-sensitive phenotype of the N-14 mutant also
supports the notion that this region is important for protein
conformation.
Our data do not support a primary defect in fusion or binding for the
PRR mutants. Even the truncation of 49 of the 61 amino acids from the
C-terminus of the PRR gave a titer that was still 10% of the E/A-PRR
titer in a retroviral vector, and the N-14 mutant produced wild-type
levels of syncytia in a fusion assay. In addition, although the PRR has
been shown to be able to influence the receptor-binding properties of
certain MuLV subtypes (3, 16), it is likely that this effect
is also secondary to an influence on the overall protein structure.
However, we cannot rule out the possibility that the PRR plays a
different role in different MuLV subtypes. Our analysis is consistent
with a role for the PRR in the proper processing of Pr85 and the stable
association of the SU and TM subunits, with downstream effects on
fusion and infectivity.
 |
ACKNOWLEDGMENTS |
We thank Ling Lu and Michael J. Skotzko for technical assistance
and Lingtao Wu for helpful discussions.
This work was supported by Genetic Therapy, Inc. (GTI)/Novartis
(Gaithersburg, Md.) and by NIH grant CA59318-04.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Norris Cancer
Center, Rm. 633, University of Southern California School of Medicine, 1441 Eastlake Ave., Los Angeles, CA 90033. Phone: (213) 764-0673. Fax:
(213) 764 0097. E-mail: pcannon{at}hsc.usc.edu.
 |
REFERENCES |
| 1.
|
Albritton, L. M.,
J. W. Kim,
L. Tseng,
D. Scadden, and J. M. Cunningham.
1993.
Envelope-binding domain in the cationic amino acid transporter determines the host range of ecotropic murine retroviruses.
J. Virol.
67:2091-2096[Abstract/Free Full Text].
|
| 2.
|
Andersen, K. B.
1994.
A domain of murine retrovirus surface protein gp70 mediates cell fusion, as shown in a novel SC-1 cell fusion system.
J. Virol.
68:3175-3182[Abstract/Free Full Text].
|
| 3.
|
Battini, J. L.,
J. M. Heard, and O. Danos.
1992.
Receptor choice determinants in the envelope proteins of amphotropic, xenotropic, and polytropic murine leukemia viruses.
J. Virol.
66:1468-1475[Abstract/Free Full Text].
|
| 4.
| Benedict, C. A., Y. Zhao, N. Kasahara, P. M. Cannon, and W. F. Anderson. Development of retroviral vectors
that target hematopoietic stem cells. Hematopoietic cell therapy.
In A. D. Ho and R. E. Champlin (ed.),
Hematopoietic stem cell therapy, in press. Cambridge University Press,
Cambridge, United Kingdom.
|
| 5.
|
Bosselman, R. A.,
F. van Straten,
C. van Beveren,
I. M. Verma, and M. Vogt.
1982.
Analysis of the env gene of a molecularly cloned and biologically active Moloney mink cell focus-forming proviral DNA.
J. Virol.
44:19-31[Abstract/Free Full Text].
|
| 6.
|
Cosset, F. L., and S. J. Russell.
1996.
Targeting retrovirus entry.
Gene Ther.
3:946-956[Medline].
|
| 7.
|
Delassus, S.,
P. Sonigo, and S. Wain-Hobson.
1989.
Genetic organization of gibbon ape leukemia virus.
Virology
53:205-213.
|
| 8.
|
Dong, J.,
J. W. Dubay,
L. G. Perez, and E. Hunter.
1992.
Mutations within the proteolytic cleavage site of the Rous sarcoma virus glycoprotein define a requirement for dibasic residues for intracellular cleavage.
J. Virol.
66:865-874[Abstract/Free Full Text].
|
| 9.
|
Elder, J. H.,
J. S. McGee,
M. Munson,
J. L. Bittle, and C. Grant.
1987.
Localization of neutralization regions of the envelope gene of feline leukemia virus by using anti-synthetic peptide antibodies.
J. Virol.
61:8-15[Abstract/Free Full Text].
|
| 10.
|
Evans, L. H.,
R. P. Morrison,
F. G. Malik,
J. Portis, and W. J. Britt.
1990.
A neutralizeable epitope common to the envelope glycoproteins of ecotropic, polytropic, xenotropic, and amphotropic murine leukemia viruses.
J. Virol.
64:6176-6183[Abstract/Free Full Text].
|
| 11.
|
Fontenot, J. D.,
N. Tjandra,
C. Ho,
P. C. Andrews, and R. C. Montelaro.
1994.
Structure and self assembly of a retrovirus (FeLV) proline rich neutralization domain.
J. Biomol. Struct. Dyn.
11:821-837[Medline].
|
| 12.
|
Freed, E. O., and R. Risser.
1987.
The role of envelope glycoprotein processing in murine leukemia virus infection.
J. Virol.
61:2852-2856[Abstract/Free Full Text].
|
| 13.
|
Gilbert, J. M.,
D. L. Hernandez,
K. W. Balliet,
P. Bates, and J. M. White.
1995.
Receptor-induced conformational changes in the subgroup A avian leukosis and sarcoma virus envelope glycoprotein.
J. Virol.
69:7410-7415[Abstract].
|
| 14.
|
Gray, K. D., and M. J. Roth.
1993.
Mutational analysis of the envelope gene of Moloney murine leukemia virus.
J. Virol.
67:3489-3496[Abstract/Free Full Text].
|
| 15.
|
Green, N.,
T. M. Shinnick,
O. Witte,
A. Ponticelli,
J. G. Sutcliffe, and R. A. Lerner.
1981.
Sequence-specific antibodies show that maturation of Moloney murine leukemia virus envelope polyprotein involves removal of a COOH-terminal peptide.
Proc. Natl. Acad. Sci. USA
78:6023-6027[Abstract/Free Full Text].
|
| 16.
|
Han, J.,
P. M. Cannon,
K. Lai,
Y. Zhao,
M. V. Eiden, and W. F. Anderson.
1997.
Identification of envelope protein residues required for the expanded range of 10A1 murine leukemia virus.
J. Virol.
71:8103-8108[Abstract].
|
| 17.
|
Helseth, E.,
U. Olshevsky,
C. Furman, and J. Sodroski.
1991.
Human immunodeficiency virus type 1 gp120 envelope glycoprotein regions important for association with the gp41 transmembrane glycoprotein.
J. Virol.
65:2119-2123[Abstract/Free Full Text].
|
| 18.
|
Ho, S. N.,
H. D. Hunt,
R. M. Horton,
J. K. Pullen, and L. R. Please.
1989.
Site-directed mutagenesis by overlap extension using polymerase chain reaction.
Gene
77:51-59[Medline].
|
| 19.
|
Hunter, E., and R. Swanstrom.
1992.
Retrovirus envelope glycoproteins.
Curr. Top. Microbiol. Immunol.
157:187-253.
|
| 20.
|
Januszeski, M. M.,
P. M. Cannon,
D. Chen,
Y. Rozenberg, and W. F. Anderson.
1997.
Functional analysis of the cytoplasmic tail of Moloney murine leukemia virus envelope protein.
J. Virol.
71:3613-3619[Abstract].
|
| 21.
|
Koch, W.,
G. Hunsmann, and R. Friedrich.
1983.
Nucleotide sequence of the envelope gene of Friend murine leukemia virus.
J. Virol.
45:1-9[Abstract/Free Full Text].
|
| 22.
|
Li, I.,
A. Pinter, and S. C. Kayman.
1997.
The critical N-linked glycan of murine leukemia virus envelope protein promotes both folding of the C-terminal domains of the precursor polyprotein and stability of the postcleavage envelope complex.
J. Virol.
71:7012-7019[Abstract].
|
| 23.
|
MacKrell, A. J.,
N. W. Soong,
C. M. Curtis, and W. F. Anderson.
1996.
Identification of a subdomain in the Moloney murine leukemia virus envelope protein involved in receptor binding.
J. Virol.
70:1768-1774[Abstract].
|
| 24.
|
McCune, J. M.,
L. B. Rabin,
M. B. Feinberg,
M. Lieberman,
J. C. Kosek,
G. R. Reyes, and I. L. Weissman.
1988.
Endoproteolytic cleavage of gp160 is required for the activation of human immunodeficiency virus.
Cell
53:55-67[Medline].
|
| 25.
|
Morgan, R. A.,
O. Nussbaum,
D. D. Muenchau,
L. Shu,
L. Couture, and W. F. Anderson.
1993.
Analysis of the functional and host range-determining regions of the murine ecotropic and amphotropic retrovirus envelope proteins.
J. Virol.
67:4712-4721[Abstract/Free Full Text].
|
| 26.
|
Nick, S.,
J. Klaws,
K. Freibel,
C. Birr,
G. Hunsmann, and H. Bayer.
1990.
Virus neutralizing and enhancing epitopes characterized by synthetic oligopeptides derived from the feline leukemia virus glycoprotein sequence gp70.
J. Gen. Virol.
71:77-83[Abstract/Free Full Text].
|
| 27.
|
Nunberg, J. H.,
G. Rogers,
J. H. Gilbert, and R. M. Snead.
1984.
Method to map antigenic determinants recognized by monoclonal antibodies: localization of a determinant virus neutralization on the feline leukemia virus envelope protein.
Proc. Natl. Acad. Sci. USA
81:3675-3679[Abstract/Free Full Text].
|
| 28.
|
Ott, D.,
R. Friedrich, and A. Rein.
1990.
Sequence analysis of amphotropic and 10A1 murine leukemia viruses: close relationship to mink cell focus-inducing viruses.
J. Virol.
64:757-766[Abstract/Free Full Text].
|
| 29.
|
Park, B. H.,
B. Matuschke,
E. Lavi, and G. N. Gaulton.
1994.
A point mutation in the env gene of a murine leukemia virus induces syncytium formation and neurologic disease.
J. Virol.
68:7516-7524[Abstract/Free Full Text].
|
| 30.
|
Pinter, A., and E. Fleissner.
1977.
The presence of disulfide-linked gp70-p15(E) complexes in AKR murine leukemia virus.
Virology
83:417-422[Medline].
|
| 31.
|
Pinter, A.,
W. J. Honnen,
J. S. Tung,
P. V. O'Donnell, and U. Hammerling.
1982.
Structural domains of endogenous murine leukemia virus gp70s containing specific antigenic determinants defined by monoclonal antibodies.
Virology
116:499-516[Medline].
|
| 32.
|
Pinter, A.,
R. Kopelman,
Z. Li,
S. C. Kayman, and D. A. Sanders.
1997.
Localization of the labile disulfide bond between SU and TM of the murine leukemia virus envelope protein complex to a highly conserved CWLC motif in SU that resembles the active-site sequence of thiol-disulfide exchange enzyme.
J. Virol.
71:8073-8077[Abstract].
|
| 33.
|
Ragheb, J. A., and W. F. Anderson.
1994.
Uncoupled expression of Moloney murine leukemia virus envelope polypeptides SU and TM: a functional analysis of the role of TM domains in viral entry.
J. Virol.
68:3207-3219[Abstract/Free Full Text].
|
| 34.
|
Rein, A.,
J. Mirro,
J. G. Haynes,
S. M. Ernst, and K. Nagashima.
1994.
Function of the cytoplasmic domain of a retroviral transmembrane protein: p15E-p2E cleavage activates the membrane fusion capability of the murine leukemia virus Env protein.
J. Virol.
68:1773-1781[Abstract/Free Full Text].
|
| 35.
|
Sattentau, Q. J., and J. P. Moore.
1991.
Conformational change induced in the human immunodeficiency virus envelope protein by soluble CD4.
J. Exp. Med.
174:407-415[Abstract/Free Full Text].
|
| 36.
|
Schilz, T. F.,
B. A. Jameson,
L. Lopalco,
A. G. Siccardi,
R. A. Weissman, and J. P. Moore.
1992.
Conserved structural features in the interaction between retroviral surface and transmembrane glycoproteins.
AIDS Res. Hum. Retroviruses
18:1571-1580.
|
| 37.
|
Soneoka, Y.,
P. M. Cannon,
E. E. Ramsdale,
J. C. Griffiths,
G. Romano,
S. M. Kingsman, and A. J. Kingsman.
1995.
A transient three plasmid expression system for the production of high titre retroviral vectors.
Nucleic Acids Res.
23:626-633.
|
| 38.
|
Spies, P. C., and R. W. Compans.
1993.
Alternate pathways of secretion of simian immunodeficiency virus envelope glycoproteins.
J. Virol.
67:6536-6541.
|
| 39.
|
Takagi, J.,
H. Asai, and Y. Saito.
1992.
A collagen/gelatin-binding decapeptide derived from bovine propolypeptide of von Willebrand factor.
Biochemistry
32:8530-8534.
|
| 40.
|
Tucker, P. W.,
J. L. Sligntom, and F. R. Blattner.
1981.
Mouse IgA heavy chain gene sequence: implications for evolution of immunoglobulin hinge exons.
Proc. Natl. Acad. Sci. USA
78:7684-7688[Abstract/Free Full Text].
|
| 41.
|
Valsesia-Wittmann, S.,
F. J. Morling,
T. Hatziioannous,
S. J. Russell, and F. Cosset.
1997.
Receptor co-operation in retrovirus entry: recruitment of an auxiliary entry mechanism after retargeted binding.
EMBO J.
160:1214-1223.
|
| 42.
|
Weiss, R. A.
1993.
Cellular receptors and viral glycoproteins involved in retrovirus entry, p. 1-108.
In
J. A. Levy (ed.), The Retroviridae. Plenum Press, New York, N.Y.
|
| 43.
|
White, J. M.
1992.
Membrane fusion.
Science
258:917-924[Abstract/Free Full Text].
|
| 44.
|
Wilson, C. A.,
J. W. Marsh, and M. V. Eiden.
1992.
The requirements for viral entry differ from those for virally induced syncytium formation in NIH 3T3/DTras cells exposed to Moloney murine leukemia virus.
J. Virol.
66:7262-7269[Abstract/Free Full Text].
|
| 45.
|
Zhao, Y.,
S. Lee, and W. F. Anderson.
1997.
Functional interactions between monomers of the retroviral envelope protein complex.
J. Virol.
71:6967-6972[Abstract].
|
| 46.
|
Zhu, N. L.,
P. M. Cannon,
D. Chen, and W. F. Anderson.
1998.
Mutational analysis of the fusion peptide of Moloney murine leukemia virus transmembrane protein p15E.
J. Virol.
72:1632-1639[Abstract/Free Full Text].
|
J Virol, July 1998, p. 5383-5391, Vol. 72, No. 7
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Ryu, B. Y., Zavorotinskaya, T., Trentin, B., Albritton, L. M.
(2008). The block to membrane fusion differs with the site of ligand insertion in modified retroviral envelope proteins. J. Gen. Virol.
89: 1049-1058
[Abstract]
[Full Text]
-
Ou, W., Silver, J.
(2006). Stoichiometry of Murine Leukemia Virus Envelope Protein-Mediated Fusion and Its Neutralization. J. Virol.
80: 11982-11990
[Abstract]
[Full Text]
-
Ou, W., Lu, N., Yu, S. S., Silver, J.
(2006). Effect of Epitope Position on Neutralization by Anti-Human Immunodeficiency Virus Monoclonal Antibody 2F5. J. Virol.
80: 2539-2547
[Abstract]
[Full Text]
-
Chang, K. W., Barsov, E. V., Ferris, A. L., Hughes, S. H.
(2005). Mutations of a Residue within the Polyproline-Rich Region of Env Alter the Replication Rate and Level of Cytopathic Effects in Chimeric Avian Retroviral Vectors. J. Virol.
79: 10258-10267
[Abstract]
[Full Text]
-
Wallin, M., Ekstrom, M., Garoff, H.
(2005). The Fusion-Controlling Disulfide Bond Isomerase in Retrovirus Env Is Triggered by Protein Destabilization. J. Virol.
79: 1678-1685
[Abstract]
[Full Text]
-
Harrison, I., Takeuchi, Y., Bartosch, B., Stoye, J. P.
(2004). Determinants of High Titer in Recombinant Porcine Endogenous Retroviruses. J. Virol.
78: 13871-13879
[Abstract]
[Full Text]
-
Ye, K., Jin, S., Ataai, M. M., Schultz, J. S., Ibeh, J.
(2004). Tagging Retrovirus Vectors with a Metal Binding Peptide and One-Step Purification by Immobilized Metal Affinity Chromatography. J. Virol.
78: 9820-9827
[Abstract]
[Full Text]
-
Bahrami, S., Duch, M., Pedersen, F. S.
(2004). Change of Tropism of SL3-2 Murine Leukemia Virus, Using Random Mutational Libraries. J. Virol.
78: 9343-9351
[Abstract]
[Full Text]
-
Qian, Z., Albritton, L. M.
(2004). An Aromatic Side Chain Is Required at Residue 8 of SU for Fusion of Ecotropic Murine Leukemia Virus. J. Virol.
78: 508-512
[Abstract]
[Full Text]
-
O'Reilly, L., Roth, M. J.
(2003). G541R within the 4070A TM Protein Regulates Fusion in Murine Leukemia Viruses. J. Virol.
77: 12011-12021
[Abstract]
[Full Text]
-
Burkhart, M. D., Kayman, S. C., He, Y., Pinter, A.
(2003). Distinct Mechanisms of Neutralization by Monoclonal Antibodies Specific for Sites in the N-Terminal or C-Terminal Domain of Murine Leukemia Virus SU. J. Virol.
77: 3993-4003
[Abstract]
[Full Text]
-
Maury, W., Wright, P. J., Bradley, S.
(2003). Characterization of a Cytolytic Strain of Equine Infectious Anemia Virus. J. Virol.
77: 2385-2399
[Abstract]
[Full Text]
-
Erlwein, O., Buchholz, C. J., Schnierle, B. S.
(2003). The proline-rich region of the ecotropic Moloney murine leukaemia virus envelope protein tolerates the insertion of the green fluorescent protein and allows the generation of replication-competent virus. J. Gen. Virol.
84: 369-373
[Abstract]
[Full Text]
-
Aguilar, H. C., Anderson, W. F., Cannon, P. M.
(2002). Cytoplasmic Tail of Moloney Murine Leukemia Virus Envelope Protein Influences the Conformation of the Extracellular Domain: Implications for Mechanism of Action of the R Peptide. J. Virol.
77: 1281-1291
[Abstract]
[Full Text]
-
Lavillette, D., Ruggieri, A., Boson, B., Maurice, M., Cosset, F.-L.
(2002). Relationship between SU Subdomains That Regulate the Receptor-Mediated Transition from the Native (Fusion-Inhibited) to the Fusion-Active Conformation of the Murine Leukemia Virus Glycoprotein. J. Virol.
76: 9673-9685
[Abstract]
[Full Text]
-
Jung, Y. T., Lyu, M. S., Buckler-White, A., Kozak, C. A.
(2002). Characterization of a Polytropic Murine Leukemia Virus Proviral Sequence Associated with the Virus Resistance Gene Rmcf of DBA/2 Mice. J. Virol.
76: 8218-8224
[Abstract]
[Full Text]
-
Rothenberg, S. M., Olsen, M. N., Laurent, L. C., Crowley, R. A., Brown, P. O.
(2001). Comprehensive Mutational Analysis of the Moloney Murine Leukemia Virus Envelope Protein. J. Virol.
75: 11851-11862
[Abstract]
[Full Text]
-
Ikeda, H., Kato, K., Kitani, H., Suzuki, T., Yoshida, T., Inaguma, Y., Yamamoto, N., Suh, J.-G., Hyun, B.-H., Yamagata, T., Namikawa, T., Tomita, T.
(2001). Virological Properties and Nucleotide Sequences of Cas-E-Type Endogenous Ecotropic Murine Leukemia Viruses in South Asian Wild Mice, Mus musculus castaneus. J. Virol.
75: 5049-5058
[Abstract]
[Full Text]
-
Barnett, A. L., Davey, R. A., Cunningham, J. M.
(2001). Modular organization of the Friend murine leukemia virus envelope protein underlies the mechanism of infection. Proc. Natl. Acad. Sci. USA
98: 4113-4118
[Abstract]
[Full Text]
-
Bachrach, E., Marin, M., Pelegrin, M., Karavanas, G., Piechaczyk, M.
(2000). Efficient Cell Infection by Moloney Murine Leukemia Virus-Derived Particles Requires Minimal Amounts of Envelope Glycoprotein. J. Virol.
74: 8480-8486
[Abstract]
[Full Text]
-
Gordon, E. M., Liu, P. X., Chen, Z. H., Liu, L., Whitley, M. D., Gee, C., Groshen, S., Hinton, D. R., Beart, R. W., Hall, F. L.
(2000). Inhibition of Metastatic Tumor Growth in Nude Mice by Portal Vein Infusions of Matrix-targeted Retroviral Vectors Bearing a Cytocidal Cyclin G1 Construct. Cancer Res.
60: 3343-3347
[Abstract]
[Full Text]
-
Liu, L., Liu, L., Anderson, W. F., Beart, R. W., Gordon, E. M., Hall, F. L.
(2000). Incorporation of Tumor Vasculature Targeting Motifs into Moloney Murine Leukemia Virus Env Escort Proteins Enhances Retrovirus Binding and Transduction of Human Endothelial Cells. J. Virol.
74: 5320-5328
[Abstract]
[Full Text]
-
Jobbagy, Z., Garfield, S., Baptiste, L., Eiden, M. V., Anderson, W. B.
(2000). Subcellular Redistribution of Pit-2 Pi Transporter/Amphotropic Leukemia Virus (A-MuLV) Receptor in A-MuLV-Infected NIH 3T3 Fibroblasts: Involvement in Superinfection Interference. J. Virol.
74: 2847-2854
[Abstract]
[Full Text]
-
O'Reilly, L., Roth, M. J.
(2000). Second-Site Changes Affect Viability of Amphotropic/Ecotropic Chimeric Enveloped Murine Leukemia Viruses. J. Virol.
74: 899-913
[Abstract]
[Full Text]
-
Kayman, S. C., Park, H., Saxon, M., Pinter, A.
(1999). The Hypervariable Domain of the Murine Leukemia Virus Surface Protein Tolerates Large Insertions and Deletions, Enabling Development of a Retroviral Particle Display System. J. Virol.
73: 1802-1808
[Abstract]
[Full Text]
-
Lavillette, D., Maurice, M., Roche, C., Russell, S. J., Sitbon, M., Cosset, F.-L.
(1998). A Proline-Rich Motif Downstream of the Receptor Binding Domain Modulates Conformation and Fusogenicity of Murine Retroviral Envelopes. J. Virol.
72: 9955-9965
[Abstract]
[Full Text]